Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors

US8148391B2 · kind B2 · utility

Assignee

• Cephalon LLC · US

Inventors

• Gulzar Ahmed · Yardley, US
• Henry J. Breslin · Lansdale, US
• Jason P. Burke · Houston, US
• Matthew A. Curry · Coatesville, US
• James L. Diebold · Norristown, US
• Bruce D. Dorsey · Ambler, US
• Benjamin J. Dugan · Glen Mills, US
• Daming Feng · Plainsboro, US
• Diane E. Gingrich · Downingtown, US
• Tao Guo
• Keith S. Learn · Perkiomenville, US
• Joseph Lisko · Collegeville, US
• Rong Liu · Kendall Park, US
• Eugen F. Mesaros · Wallingford, US
• Karen L. Milkiewicz · Exton, US
• Gregory R. Ott · West Chester, US
• Jay Theroff · West Chester, US
• Tho V. Thieu · Ambler, US
• Rabindranath Tripathy · Nazareth, US
• Theodore L. Underiner · Malvern, US
• Gregory J. Wells · Fairfield, US
• Craig A. Zificsak · Downingtown, US

Key dates

• Filing date: Oct 23, 2007
• Grant date: Apr 3, 2012
• Expiry date: Nov 1, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.